We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

InSights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Vitamin B Supplements Could Aid Glaucoma, Slowing Disease Progression

Source: Pharmacy Times articles New research reveals that B vitamins and choline may slow glaucoma progression, offering hope for innovative treatments beyond traditional methods. Read More

FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC

Source: Pharmacy Times articles With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC). Read More

Obicetrapib Plus Ezetimibe Reduced LDL-C in Patients With or at Risk of Atherosclerotic Cardiovascular Disease

Source: Pharmacy Times articles The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo. Read More

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Source: Pharmacy Times articles Post Content Read More

The Role of Physical Activity in Breast Cancer Risk Reduction and Survival

Source: Pharmacy Times articles Pharmacists can educate patients on non-pharmacologic strategies that help improve survival outcomes. Read More
Latest Data

Latest Publications

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks...

Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review

Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT...

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background:...

Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis

Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead...

Email

info@myeloma360.com